Kyntra Bio, Inc. (LON:0IL8)
7.45
-0.20 (-2.61%)
At close: Feb 12, 2026
Kyntra Bio Revenue
Kyntra Bio had revenue of $1.08M USD in the quarter ending September 30, 2025, with 774.80% growth. This brings the company's revenue in the last twelve months to $8.30M, down -84.53% year-over-year. In the year 2024, Kyntra Bio had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$8.30M
Revenue Growth
-84.53%
P/S Ratio
3.60
Revenue / Employee
$36.88K
Employees
225
Market Cap
22.21M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
| Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
| Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
| Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
| Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
| Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
| Dec 31, 2012 | 65.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Abingdon Health | 8.43M |
| Palatin Technologies | 6.58M |
| Arecor Therapeutics | 5.06M |
| Renalytix | 2.19M |
Kyntra Bio News
- 5 weeks ago - FibroGen (FGEN) Faces Option Delistings as of January 8th - GuruFocus
- 5 weeks ago - FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
- 5 weeks ago - FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewsWire
- 2 months ago - FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
- 2 months ago - FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS - Nasdaq
- 3 months ago - FibroGen, Inc. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... - GuruFocus
- 3 months ago - Q3 2025 FibroGen Inc Earnings Call Transcript - GuruFocus